The FDA has qualified its first artificial intelligence tool to help drug developers evaluate fatty liver disease in their clinical trials. The agency gave a green light to the AI-Based Histologic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback